Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Repligen Cp (RGEN)

Repligen Cp (RGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,242,861
  • Shares Outstanding, K 52,059
  • Annual Sales, $ 194,030 K
  • Annual Income, $ 16,620 K
  • 60-Month Beta 1.12
  • Price/Sales 18.96
  • Price/Cash Flow 89.22
  • Price/Book 4.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.18
  • Number of Estimates 7
  • High Estimate 0.20
  • Low Estimate 0.17
  • Prior Year 0.21
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.82 +14.68%
on 12/18/19
101.00 -0.29%
on 01/15/20
+10.32 (+11.42%)
since 12/17/19
3-Month
76.75 +31.23%
on 10/25/19
101.00 -0.29%
on 01/15/20
+21.45 (+27.06%)
since 10/17/19
52-Week
52.87 +90.49%
on 04/18/19
101.00 -0.29%
on 01/15/20
+43.96 (+77.46%)
since 01/17/19

Most Recent Stories

More News
ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why

ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.

ACAD : 43.43 (-2.54%)
RGEN : 100.71 (+0.81%)
EPZM : 26.72 (+4.62%)
AXSM : 90.34 (-2.31%)
Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Company will present at the 38 annual J.P. Morgan Healthcare Conference,...

JPM : 138.20 (+0.69%)
RGEN : 100.71 (+0.81%)
SmarTrend Watching for Potential Rebound in Shares of Repligen Corp After 1.72% Loss

Repligen Corp (NASDAQ:RGEN) traded in a range yesterday that spanned from a low of $90.90 to a high of $93.49. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $91.68...

RGEN : 100.71 (+0.81%)
Has Repligen (RGEN) Outpaced Other Medical Stocks This Year?

Is (RGEN) Outperforming Other Medical Stocks This Year?

RGEN : 100.71 (+0.81%)
3 Reasons Growth Investors Will Love Repligen (RGEN)

Repligen (RGEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

RGEN : 100.71 (+0.81%)
Here's Why Repligen (RGEN) is a Great Momentum Stock to Buy

Does Repligen (RGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

RGEN : 100.71 (+0.81%)
Watch for Repligen Corp to Potentially Pullback After Gaining 3.80% Yesterday

Repligen Corp (NASDAQ:RGEN) traded in a range yesterday that spanned from a low of $84.59 to a high of $87.26. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of...

RGEN : 100.71 (+0.81%)
SmarTrend Watching for Potential Rebound in Shares of Repligen Corp After 1.68% Loss

Repligen Corp (NASDAQ:RGEN) traded in a range yesterday that spanned from a low of $82.95 to a high of $85.37. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $84.40...

RGEN : 100.71 (+0.81%)
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?

Is (RGEN) Outperforming Other Medical Stocks This Year?

RGEN : 100.71 (+0.81%)
Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance

Repligen (RGEN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

ACOR : 2.07 (-3.72%)
BGNE : 170.36 (+1.50%)
ANIK : 45.43 (-3.57%)
RGEN : 100.71 (+0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade RGEN with:

Business Summary

Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide....

See More

Key Turning Points

2nd Resistance Point 101.68
1st Resistance Point 101.19
Last Price 100.71
1st Support Level 99.94
2nd Support Level 99.18

See More

52-Week High 101.00
Last Price 100.71
Fibonacci 61.8% 82.61
Fibonacci 50% 76.93
Fibonacci 38.2% 71.26
52-Week Low 52.87

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar